<?xml version="1.0" encoding="UTF-8"?>
<GLOSSARY>
  <INFO>
    <NAME>Methodologies for developing national treatment guidelines</NAME>
    <INTRO>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.&lt;br&gt;&lt;/p&gt;</INTRO>
    <INTROFORMAT>1</INTROFORMAT>
    <ALLOWDUPLICATEDENTRIES>0</ALLOWDUPLICATEDENTRIES>
    <DISPLAYFORMAT>entrylist</DISPLAYFORMAT>
    <SHOWSPECIAL>1</SHOWSPECIAL>
    <SHOWALPHABET>1</SHOWALPHABET>
    <SHOWALL>1</SHOWALL>
    <ALLOWCOMMENTS>1</ALLOWCOMMENTS>
    <USEDYNALINK>1</USEDYNALINK>
    <DEFAULTAPPROVAL>1</DEFAULTAPPROVAL>
    <GLOBALGLOSSARY>0</GLOBALGLOSSARY>
    <ENTBYPAGE>10</ENTBYPAGE>
    <ENTRIES>
      <ENTRY>
        <CONCEPT>The FAO Action Plan on Antimicrobial Resistance 2021–2025</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Author(s) &lt;/strong&gt;FAO&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication date&lt;/strong&gt; 2021&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication type&lt;/strong&gt; Action plan&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Keywords &lt;/strong&gt;Antimicrobial resistance; action plans; FAO; good practices; governance.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;Due to antimicrobial resistance (AMR), drug-resistant infections are placing an ever-increasing burden on human, animal, plant, and environmental health. Drug-resistant infections have the potential to become leading causes of death. AMR may force tens of millions more people into extreme poverty, hunger, and malnutrition, and the associated economic losses are projected at several percent of gross domestic product. However, we can prevent this from happening – if we act quickly.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;This document outlines the FAO Action Plan on Antimicrobial Resistance 2021–2025 which serves as a roadmap for focusing global efforts to address AMR in the food and agriculture sectors. The aim of this plan is to help accelerate progress in developing and implementing multi-sectoral National Action Plans to tackle AMR by calling attention to strategic priorities and areas of expertise for FAO support.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;The action plan was developed by a multidisciplinary FAO team to ensure that all relevant dimensions – including terrestrial and aquatic animal health and production, crop production, food and feed safety, genetic resources, natural resource management, risk communication, and behavior change - are considered, with attention to regulatory frameworks, standards, norm-setting and bottom-up processes of collective action. By working together, food systems, livelihoods, and economies will be better protected from the destabilizing forces of untreatable illness.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Format &lt;/strong&gt;PDF&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Licensing &lt;/strong&gt;&lt;span&gt;Some rights reserved. This work is made available under the Creative Commons &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;https://creativecommons.org/licenses/by-nc-sa/3.0/igo/legalcode).&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;DOI&lt;/strong&gt; &lt;a href=&quot;https://doi.org/10.4060/cb5545en&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://doi.org/10.4060/cb5545en&lt;/a&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;ISBN &lt;/strong&gt;&lt;span&gt;978-92-5-134673-0&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;External Link &lt;/strong&gt;&lt;a href=&quot;https://www.fao.org/documents/card/en/c/cb5545en&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://www.fao.org/documents/card/en/c/cb5545en&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>1</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>Action plan</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Chinese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>FAO</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Technical assistance for animal health systems to minimize the impacts of antimicrobial resistance in Asia</CONCEPT>
        <DEFINITION>&lt;p&gt;&lt;strong&gt;Author(s) &lt;/strong&gt;FAO, Mary Joy Gordoncillo (RAP, ECTAD)&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Period&lt;/strong&gt; 1 October 2020—30 September 2024&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication type&lt;/strong&gt;&amp;nbsp;Project&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Donor&lt;/strong&gt; USA&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Keywords&lt;/strong&gt; AMR; AMU.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;Objectives: &lt;/span&gt;Further enhance coordination and collaboration among AMR multi-sectoral stakeholders, increase institutional and multi-disciplinary AMR and AMU workforce capacity, promote preparedness and response of animal health systems, and increase adoption of good risk reduction practices along the value and supply chain.&lt;br&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Outcomes and outputs:&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Outcome 1: Enhanced coordination and collaboration among multi-sectoral stakeholders&amp;nbsp;&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;ul&gt;&lt;li&gt;Output 1.1: Multi-sectoral and multi-lateral coordination mechanisms are initiated, operationalized, and/or scaled up.&lt;/li&gt;&lt;li&gt;Output 1.2: AMR stakeholder engagement expanded and enhanced for actions.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Outcome 2: Enhanced institutional and multi-disciplinary workforce capacity&lt;ul&gt;&lt;li&gt;&lt;ul&gt;&lt;li&gt;Output 2.1: Multi-disciplinary workforce capacities on behavioural change, AMR surveillance, AMR governance and good practices are strengthened.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Outcome 3: Enhanced preparedness and responses of animal health systems&lt;ul&gt;&lt;li&gt;&lt;ul&gt;&lt;li&gt;Output 3.1: AMR surveillance in the region is expanded, sustained and progressively improved.&lt;/li&gt;&lt;li&gt;Output 3.2: AMR data management and utility towards evidence-based interventions is strengthened.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Outcome 4: Increased adoption of good risk reduction practices along the value and supply chain&lt;ul&gt;&lt;li&gt;&lt;ul&gt;&lt;li&gt;Output 4.1: Good farming practices for AMR risk reduction is strengthened, promoted and reinforced&amp;nbsp;&lt;/li&gt;&lt;li&gt;Output 4.2: Antimicrobial stewardship is strategically advocated.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;h1&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;Language&lt;span style=&quot;font-weight:normal;&quot;&gt; English&lt;/span&gt;&lt;/span&gt;&lt;/h1&gt;&lt;h1&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;Format&lt;span style=&quot;font-weight:normal;&quot;&gt; Website&lt;/span&gt;&lt;/span&gt;&lt;/h1&gt;&lt;h1&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;External Link&amp;nbsp;&lt;span style=&quot;font-weight:normal;&quot;&gt;&lt;a href=&quot;https://www.fao.org/antimicrobial-resistance/projects/ongoing/project-9/en/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://www.fao.org/antimicrobial-resistance/projects/ongoing/project-9/en/&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/h1&gt;&lt;br&gt;
&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>FAO</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>PROTECT ME Responsible antibacterial use in the veterinary community</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;strong&gt;Author(s)&lt;/strong&gt; BSAVA/SAMSoc&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication date&lt;/strong&gt; November 2018&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication type &lt;/strong&gt;Poster&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;The key principles that should be considered before giving antibacterials. These principles are developed in the following sections. A &lt;a href=&quot;https://www.bsavalibrary.com/deliver/fulltext/10.22233/9781910443644/bsava_samsoc_protectmeposter_011118web.pdf?itemId=%2Fcontent%2Fsuppdata%2F10.22233%2F9781910443644.chap6_1-S1&amp;amp;mimeType=pdf&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;downloadable PDF of the PROTECT ME poster&lt;/a&gt; (updated November 2023), together with the PROTECT poster for rabbits, are provided with this chapter as supplementary content.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Introduction&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The PROTECT message developed out of a SAMSoc initiative to review and promote responsible antibacterial prescribing. This led to the original PROTECT poster produced by BSAVA and SAMSoc, which has been revised in 2018.&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;BEFORE you give antibacterials consider the following principles:&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Reduce prophylaxis: &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Antibacterials are not a substitute for surgical asepsis and the need for prophylactic antibacterials in surgery should be carefully considered. Prophylactic antibacterials are only appropriate in a few medical cases (e.g. immune-compromised patients).&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Offer other options: &lt;/strong&gt;Consider therapeutic alternatives (e.g. lavage and debridement of infected material, analgesia, cough suppressants, fluid therapy or nutritional modification). Use topical preparations as these reduce the selection pressure on resident intestinal flora (the microbiome). Use effective hygiene techniques and antiseptics to prevent infections.&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Treat effectively: &lt;/strong&gt;Before prescribing antibacterials, consider which bacteria are likely to be involved and how effectively the chosen drug will penetrate the target site. Use the shortest effective course and avoid underdosing. Ensure compliance with appropriate formulation and clear instructions.&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Employ narrow spectrum: &lt;/strong&gt;&lt;span&gt;Unnecessarily broad-spectrum antibacterials could promote antibacterial resistance, whilst selecting narrow-spectrum antibacterials limits the effects on commensal bacteria. Use culture results to support de-escalation (switching to a narrower spectrum antibacterial) whenever possible.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Culture appropriately: &lt;/strong&gt;&lt;span&gt;A sample for culture should be collected before starting antibacterial therapy. Culture is essential when prolonged (&amp;gt;1 week) treatment courses are anticipated, when resistance is likely (e.g. hospital-acquired infections) and with life-threatening infections. If first-line treatment fails, do not use another antibacterial without culture and sensitivity results (avoid cycling antibacterials).&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt; Tailor practice policy to patients: &lt;/strong&gt;&lt;span&gt;A customised practice policy can guide antibacterial selection to address the bacterial infections and resistance patterns that you see, minimizing inappropriate use. Complete the tick boxes in your PROTECT ME poster to highlight YOUR practice’s first-line approach to each condition.&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Monitor culture results: &lt;/strong&gt;&lt;span&gt;Track and record culture profiles and update your practice policy accordingly. Monitor for preventable infections (e.g. postoperative) and alter practices if needed. Audit your own antibacterial use, particularly of critically important antibacterials (e.g. fluoroquinolones and cefovecin).&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Educate others: &lt;/strong&gt;&lt;span&gt;Share this important message to reduce the threat from multi-resistant strains of bacteria and improve the health of pets and people.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Format&lt;/strong&gt; PDF&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Licensing &lt;/strong&gt;2018 British Small Animal Veterinary Association&lt;/p&gt;&lt;p&gt;&lt;strong&gt;DOI &lt;/strong&gt;&lt;a href=&quot;https://www.bsavalibrary.com/content/chapter/10.22233/9781910443644.chap6_1&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;10.22233/9781910443644.6.1&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;External Link &lt;/strong&gt;&lt;a href=&quot;https://www.bsava.com/Resources/Veterinary-resources/PROTECT-ME/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://www.bsava.com/Resources/Veterinary-resources/PROTECT-ME/&lt;/a&gt;&lt;/p&gt;&lt;br /&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>BSAVA, SAMSoc</NAME>
          </ALIAS>
        </ALIASES>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline and Recommendation</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Poster</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>PROTECT ME</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>GRADE Framework</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;
&lt;div&gt;
    &lt;p xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot;&gt;&lt;span xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot; style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
        &lt;div&gt;
            &lt;div&gt;
                &lt;p&gt;&lt;strong&gt;Author(s)&amp;nbsp;&lt;/strong&gt;Reed Siemieniuk and Gordon Guyatt&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication date&lt;/strong&gt;&amp;nbsp;September 24, 2020&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication type &lt;/strong&gt;Guidelines and recommendations&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Keywords &lt;/strong&gt;GRADE;&amp;nbsp;framework; clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) is a transparent framework for developing and presenting summaries of evidence and provides a systematic approach for making clinical practice recommendations.[1][2][3] It is the most widely adopted tool for grading the quality of evidence and for making recommendations with over 100 organisations worldwide officially endorsing GRADE.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;References&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;ol&gt;&lt;li&gt;Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. &lt;a href=&quot;https://www.bmj.com/content/336/7651/995&quot; target=&quot;_blank&quot;&gt;What is &quot;quality of evidence&quot; and why is it important to clinicians?&lt;/a&gt; BMJ (Clinical research ed). 2008;336(7651):995-8.&lt;/li&gt;&lt;li&gt;Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. &lt;a href=&quot;https://www.bmj.com/content/336/7650/924&quot; target=&quot;_blank&quot;&gt;GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.&lt;/a&gt; BMJ (Clinical research ed). 2008;336(7650):924-6.&lt;/li&gt;&lt;li&gt;Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011;64(4):383-94.&lt;/li&gt;&lt;/ol&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Format&lt;/strong&gt; Website&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;BMJ Publishing Group Limited 2024. All rights reserved.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;External Link&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/&lt;/a&gt;&lt;/p&gt;
            &lt;/div&gt;
        &lt;/div&gt;
    &lt;/div&gt;
    &lt;p&gt;&lt;/p&gt;
&lt;/div&gt;&lt;br&gt;
&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>GRADE Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>GRADE online learning modules</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Publication type &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Online learning modules&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;These online learning modules are designed to help guideline developers and authors of systematic reviews learn how to use the GRADE approach to grade the evidence in systematic reviews, to create Summary of Findings Tables and GRADE Evidence Profiles, and move from evidence to making recommendations.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;There are two sets of modules:&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;For authors of Cochrane systematic reviews and other systematic reviewers&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;For World Health Organization (WHO) guideline developers and other guideline developers&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;Each module covers a specific topic related to GRADE and can be viewed in sequence as presented here or, depending on your learning needs, viewed in any order. Most modules are approximately 20 minutes or less and will open in an external video player tab when accessed through the links below.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Language &lt;/strong&gt;English&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Format &lt;/strong&gt;Website&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Licensing &lt;/strong&gt;Funding for the development of these modules was provided by the Cochrane Collaboration through the grant &#039;Training and Capacity Building for Summary of Findings Tables&#039; and the World Health Organization.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;External Link &lt;/strong&gt;&lt;a href=&quot;https://cebgrade.mcmaster.ca/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://cebgrade.mcmaster.ca/&lt;/a&gt;&lt;/p&gt;&lt;br /&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>GRADE Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Online learning modules</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Guideline recommendations and antimicrobial resistance: the need for a change</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Author(s) &lt;/strong&gt;Christelle Elias, Lorenzo Moja, Dominik Mertz, Mark Loeb, Gilles Forte, Nicola Magrini&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication date&lt;/strong&gt; April 2017&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication type &lt;/strong&gt;Research study&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;&lt;strong&gt;Objectives &lt;/strong&gt;Antimicrobial resistance has become a &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;global burden for which inappropriate antimicrobial use &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;is an important contributing factor. Any decisions on the &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;selection of antibiotics use should consider their effects on &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;antimicrobial resistance. The objective of this study was to &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;assess the extent to which antibiotic prescribing guidelines &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;have considered resistance patterns when making &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;recommendations for five highly prevalent infectious &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;syndromes.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;&lt;strong&gt;Design &lt;/strong&gt;We used Medline searches complemented with &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;extensive use of Web engine to identify guidelines on &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;empirical treatment of community-acquired pneumonia, &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;urinary tract infections, acute otitis media, rhinosinusitis &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;and pharyngitis. We collected data on microbiology &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;and resistance patterns and identified discrete &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;pattern categories. We assessed the extent to which &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;recommendations considered resistance, in addition to &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;efficacy and safety, when recommending antibiotics.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;&lt;strong&gt;Results &lt;/strong&gt;We identified 135 guidelines, which reported &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;a total of 251 recommendations. Most (103/135, 79%) &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;were from developed countries. Community-acquired &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;pneumonia was the syndrome mostly represented (51, &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;39%). In only 16 (6.4%) recommendations, selection of &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;empirical antibiotic was discussed in relation to resistance &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;and specific microbiological data. In a further 69 (27.5%) &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;recommendations, references were made in relation &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;to resistance, but the attempt was inconsistent. Across &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;syndromes, 12 patterns of resistance with implications &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;on recommendations were observed. 50% to 75% of &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;recommendations did not attempt to set recommendation &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;in the context of these patterns.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span&gt;&lt;strong&gt;Conclusion &lt;/strong&gt;There is consistent evidence that guidelines &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;on empirical antibiotic use did not routinely consider &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;resistance in their recommendations. Decision-makers &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;should analyse and report the extent of local resistance &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;patterns to allow better decision-making.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Language &lt;/strong&gt;English&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Format &lt;/strong&gt;PDF&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Licensing &lt;/strong&gt;This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: &lt;a href=&quot;http://creativecommons.org/licenses/by-nc/4.0/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;http://creativecommons.org/licenses/by-nc/4.0/&lt;/a&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;DOI &lt;/strong&gt;&lt;a href=&quot;https://doi.org/10.1136/bmjopen-2017-016264&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://doi.org/10.1136/bmjopen-2017-016264&lt;/a&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;External Link &lt;/strong&gt;&lt;a href=&quot;https://bmjopen.bmj.com/content/7/7/e016264&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://bmjopen.bmj.com/content/7/7/e016264&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>Infection control, microbiology, protocols &amp; guidelines, public health, therapeutics</NAME>
          </ALIAS>
        </ALIASES>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Research study</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Author(s)&lt;/strong&gt;&amp;nbsp;M.R. Lappin, J. Blondeau, D. Boothe, E.B. Breitschwerdt, L. Guardabassi, D.H. Lloyd, M.G. Papich, S.C. Rankin, J.E. Sykes, J. Turnidge, J.S. Weese&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication date&lt;/strong&gt;&amp;nbsp;10 February 2017&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication type&lt;/strong&gt;&amp;nbsp;Guideline and Recommendation&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Keywords&amp;nbsp;&lt;/strong&gt;Bronchitis; Pneumonia; Pyothorax; Rhinitis.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Abstract&amp;nbsp;&lt;/strong&gt;Respiratory tract disease can be associated with primary or secondary bacterial infections in dogs and cats and is a common reason for use and potential misuse, improper use, and overuse of antimicrobials. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, the International Society for Companion Animal Infectious Diseases convened a Working Group of clinical microbiologists, pharmacologists, and internists to share experiences, examine scientific data, review clinical trials, and develop these guidelines to assist veterinarians in making antimicrobial treatment choices for use in the management of bacterial respiratory diseases in dogs and cats.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Language&amp;nbsp;&lt;/strong&gt;English&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;File Format&amp;nbsp;&lt;/strong&gt;PDF&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;Open Access&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;DOI&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://doi.org/10.1111/jvim.14627&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://doi.org/10.1111/jvim.14627&lt;/a&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;ISSN&amp;nbsp;&lt;/strong&gt;0891-6640&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;eISSN&lt;/strong&gt;&amp;nbsp;1939-1676&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;External Link&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.14627&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.14627&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>Bronchitis, Pneumonia, Pyothorax, Rhinitis, dogs, cats</NAME>
          </ALIAS>
        </ALIASES>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline and Recommendation</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Developing, Implementing, and Monitoring the Use of Standard Treatment Guidelines</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Author(s)&amp;nbsp;&lt;/strong&gt;&lt;span&gt;Mohan P. Joshi, Principal Technical Advisor and Cluster Lead for Pharmaceutical Services, SIAPS USA,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Malaika Ludman, Technical Advisor, SIAPS USA&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication date&lt;/strong&gt;&amp;nbsp;August 2015&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication type&lt;/strong&gt; Guidelines and Recommendations&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Keywords&amp;nbsp;&lt;/strong&gt;&lt;span&gt;Standard treatment guidelines; rational medicine use; health systems strengthening;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;continuous quality improvement; quality assurance.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;STGs are designed to assist health care professionals in making decisions about appropriate, effective patient care. However, health managers often have trouble setting and meeting the high standards required of modern, developed health care systems. With stakeholders expressing concern over issues such as strength of evidence, transparency, conflicts of interest, and effective implementation, it is clear that many health care professionals need further guidance in developing and making use of STGs.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;This manual guides health professionals through the process of establishing and implementing STGs, placing special emphasis on the low- and middle-income country (LMIC) context. By including tools, templates, and success stories as well as hyperlinks to useful resources, the manual helps health practitioners understand not only important concepts of treatment guidelines, but also how they can best be used in practice.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Language &lt;/strong&gt;English&lt;/p&gt;&lt;p&gt;&lt;strong&gt;File Format&lt;/strong&gt; PDF&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;This report may be reproduced if credit is given to SIAPS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;External Link&amp;nbsp;&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;http://www.siapsprogram.org/publication/stg-how-to-manual&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;www.siapsprogram.org/publication/stg-how-to-manual&lt;/a&gt;&lt;/p&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline and Recommendation</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>The Systematic Guideline Review: Method, rationale, and test on chronic heart failure</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Author(s) &lt;/strong&gt;Christiane Muth, Jochen Gensichen, Martin Beyer, Allen Hutchinson &amp;amp; Ferdinand M Gerlach &lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication date&lt;/strong&gt; 2009&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication type &lt;/strong&gt;Guideline review&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Keywords &lt;/strong&gt;C&lt;span&gt;hronic heart failure; g&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;uideline development; e&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;vidence level; c&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;onsistency analysis; d&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;raft guideline.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Abstract&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Background &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Evidence-based guidelines have the potential to improve healthcare. However, their de-novo-development requires substantial resources – especially for complex conditions, and adaptation may be biased by contextually influenced recommendations in source guidelines. In this paper we describe a new approach to guideline development – the systematic guideline review method (SGR), and its application in the development of an evidence-based guideline for family physicians on chronic heart failure (CHF).&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Methods &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;A systematic search for guidelines was carried out. Evidence-based guidelines on CHF management in adults in ambulatory care published in English or German between the years 2000 and 2004 were included. Guidelines on acute or right heart failure were excluded. Eligibility was assessed by two reviewers, methodological quality of selected guidelines was appraised using the AGREE instrument, and a framework of relevant clinical questions for diagnostics and treatment was derived. Data were extracted into evidence tables, systematically compared by means of a consistency analysis and synthesized in a preliminary draft. Most relevant primary sources were re-assessed to verify the cited evidence. Evidence and recommendations were summarized in a draft guideline.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Results &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Of 16 included guidelines five were of good quality. A total of 35 recommendations were systematically compared: 25/35 were consistent, 9/35 inconsistent, and 1/35 un-rateable (derived from a single guideline). Of the 25 consistencies, 14 were based on consensus, seven on evidence and four differed in grading. Major inconsistencies were found in 3/9 of the inconsistent recommendations. We re-evaluated the evidence for 17 recommendations (evidence-based, differing evidence levels and minor inconsistencies) – the majority was congruent. Incongruity was found where the stated evidence could not be verified in the cited primary sources, or where the evaluation in the source guidelines focused on treatment benefits and underestimated the risks. The draft guideline was completed in 8.5 man-months. The main limitation to this study was the lack of a second reviewer.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Conclusion &lt;/strong&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;The systematic guideline review including framework development, consistency analysis and validation is an effective, valid, and resource saving-approach to the development of evidence-based guidelines.&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Format &lt;/strong&gt;PDF&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Licensing&lt;/strong&gt; Open access&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;DOI&lt;/strong&gt; &lt;a href=&quot;https://doi.org/10.1186/1472-6963-9-74&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://doi.org/10.1186/1472-6963-9-74&lt;/a&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;External Link &lt;/strong&gt;&lt;a href=&quot;https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-9-74#citeas&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-9-74#citeas&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline review</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>WHO handbook for guideline development – 2nd ed.</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;h3&gt;&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Author(s)&lt;/strong&gt; &lt;span&gt;WHO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;span&gt;&lt;strong&gt;Publication date&lt;/strong&gt;&lt;span&gt; 2014&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Publication type &lt;/strong&gt;&lt;span style=&quot;font-weight:normal;&quot;&gt;Handbook&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Keywords&lt;/strong&gt; step-by-step guidance; handbook.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;This handbook provides step-by-step guidance on how to plan, develop and publish a WHO guideline. It covers the methods, processes and procedures for producing a document that meets WHO standards.&lt;/p&gt;&lt;p&gt;Additional chapters of this handbook containing detailed guidance on selected topics are also available and new chapters will continue to be added.&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Language&lt;/strong&gt; English, Chinese&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Format&lt;/strong&gt; PDF&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;strong&gt;Licensing&lt;/strong&gt; &lt;/span&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;World Health Organization. &lt;/span&gt;All rights reserved.&lt;/p&gt;&lt;h3&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;ISBN&lt;span style=&quot;font-weight:normal;&quot;&gt; 978 92 4 154896 0&lt;/span&gt;&lt;/span&gt;&lt;/h3&gt;&lt;h3&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;/span&gt;&lt;/h3&gt;&lt;h3&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;External Link &lt;span style=&quot;font-weight:normal;&quot;&gt;&lt;a href=&quot;https://www.who.int/publications/i/item/9789241548960&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://www.who.int/publications/i/item/9789241548960&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>Chinese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Handbook</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Appraisal of Guidelines for Research &amp; Evaluation Instrument (AGREE II)</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Author(s)&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;span&gt;Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;SE, Littlejohns P, Makarski J, Zitzelsberger L, for the AGREE Next Steps Consortium.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Publication date&amp;nbsp;&lt;/strong&gt;December 2017&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Publication type&amp;nbsp;&lt;/strong&gt;Guideline and Recommendation&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;The Appraisal of Guidelines for Research &amp;amp; Evaluation Instrument (AGREE II) is a tool developed to assess the methodological quality of practice guidelines.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;The tool can be used by:&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Guideline developers;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Policy makers, health administrator, program managers and professional organizations; and&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Stakeholders (including patients/consumers, health professionals, researchers, educators and other stakeholders interested in the development and uptake of clinical guidelines).&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;The AGREE II is comprised of 23 items organized into 6 quality domains:&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ol&gt;&lt;li&gt;&lt;span&gt;Scope and purpose;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Stakeholder involvement;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Rigour of development;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Clarity of presentation;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Applicability; and&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Editorial independence.&lt;/span&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;Each of the 23 items targets various aspects of practice guideline quality. The AGREE II also includes 2 final overall assessment items that requires the appraiser to make overall judgements of the practice guideline while considering how they rated the 23 items.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;The User’s Manual is designed to guide appraisers in the use of the AGREE II. The Manual is part of the complete AGREE II document or “package” and includes specific information and guidance for each of the 23 items and the 2 overall assessment items.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Language(s)&lt;/strong&gt; English; Chinese; Japanese; Thai; Korean.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;File Formats&lt;/strong&gt; PDF&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;This document is the product of an international collaboration.&amp;nbsp;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;It may be reproduced and used for educational purposes,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;quality assurance programmes and critical appraisal of&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;guidelines. It may not be used for commercial&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;purposes or product marketing. Only approved non-English&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;language versions of the AGREE II Instrument should be used,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;where available. Offers of assistance in translation into other&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;languages are welcome, provided they conform to the&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;protocol set out by The AGREE Research Trust.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&lt;strong&gt;External Link&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://www.agreetrust.org/resource-centre/agree-ii/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;https://www.agreetrust.org/resource-centre/agree-ii/&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>AGREE II Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Chinese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Japanese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Korean</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Thai</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>World Health Organization (WHO) guidelines on use of medically important antimicrobials in food-producing animals</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Author(s)&amp;nbsp;&lt;/strong&gt;&lt;span&gt;Awa Aidara-Kane, Frederick J. Angulo, John M. Conly, Yuki Minato, Ellen K. Silbergeld, Scott A. McEwen &amp;amp; Peter J. Collignon for the WHO Guideline Development Group&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication date&lt;/strong&gt; 2018&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Publication type &lt;/strong&gt;WHO guidelines&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Keywords&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Antimicrobial resistance; a&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;ntimicrobial use; a&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;griculture; f&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;ood safety; z&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;oonoses; h&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;ealth consequences; g&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;uidelines&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Background&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Antimicrobial use in food-producing animals selects for antimicrobial resistance that can be transmitted to humans via food or other transmission routes. The World Health Organization (WHO) in 2005 ranked the medical importance of antimicrobials used in humans. In late 2017, to preserve the effectiveness of medically important antimicrobials for humans, WHO released guidelines on use of antimicrobials in food-producing animals that incorporated the latest WHO rankings.&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;WHO commissioned systematic reviews and literature reviews, and convened a Guideline Development Group (GDG) of external experts free of unacceptable conflicts-of-interest. The GDG assessed the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and formulated recommendations using a structured evidence-to-decision approach that considered the balance of benefits and harms, feasibility, resource implications, and impact on equity. The resulting guidelines were peer-reviewed by an independent External Review Group and approved by the WHO Guidelines Review Committee.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;These guidelines recommend reductions in the overall use of medically important antimicrobials in food-producing animals, including complete restriction of use of antimicrobials for growth promotion and for disease prevention (i.e., in healthy animals considered at risk of infection). These guidelines also recommend that antimicrobials identified as critically important for humans not be used in food-producing animals for treatment or disease control unless susceptibility testing demonstrates the drug to be the only treatment option.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;To preserve the effectiveness of medically important antimicrobials, veterinarians, farmers, regulatory agencies, and all other stakeholders are urged to adopt these recommendations and work towards implementation of these guidelines.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Format &lt;/strong&gt;PDF&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;DOI&lt;/strong&gt;&lt;a href=&quot;https://doi.org/10.1186/s13756-017-0294-9&quot; target=&quot;_blank&quot;&gt;&amp;nbsp;&lt;span&gt;https://doi.org/10.1186/s13756-017-0294-9&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;External Link&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;&lt;a href=&quot;https://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0294-9#rightslink&quot; target=&quot;_blank&quot;&gt;https://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0294-9#rightslink&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline and Recommendation</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>WHO Guidelines</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Step-by-step approach for   development and implementation of   hospital antibiotic policy    and  standard treatment guidelines</CONCEPT>
        <DEFINITION>&lt;p style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;B4691.pdf&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;(PLEASE ADD ABSTRACT AND LINK)&lt;/span&gt;&lt;/p&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>WHO Guidelines</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>ESGVM operating procedure for writing of veterinary  practice guidelines</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;(Please add abstract and link.)&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;File name: ESGVM_Operating_Procedure_for_writing_Veterinary_Practice_Guidelines_-_April_3.2019.pdf&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>ENOVAT Guidelines Core Group</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;Please update this entry. The title may be wrong.&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;File name: AMVBLfczST.pdf&lt;br&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Title</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span&gt;&lt;strong&gt;Author(s)&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;strong&gt;Publication date&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;strong&gt;Keywords&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;Language&lt;/span&gt;&lt;br&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;File Formats&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;strong&gt;Licensing&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;strong&gt;DOI&lt;/strong&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;strong&gt;ISBN&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;span&gt;&lt;strong&gt;External Links&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;br&gt;&lt;/span&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>GRADE Series</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;&lt;strong style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Publication date&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;January 3, 2011&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Publication type &lt;/strong&gt;Guideline and recommendations&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Keywords&amp;nbsp;&lt;/strong&gt;GRADE Guidelines; systematic reviews; clinical practice guidelines; health technology assessment; quality of evidence; strength of recommendations&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Language&lt;/strong&gt; English&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Format&lt;/strong&gt; Website&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong&gt;Licensing&amp;nbsp;&lt;/strong&gt;2011 Elsevier Inc. All rights reserved.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;strong style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;External Link&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;&lt;a href=&quot;https://www.jclinepi.com/content/jce-GRADE-Series&quot; target=&quot;_blank&quot;&gt;https://www.jclinepi.com/content/jce-GRADE-Series&lt;/a&gt;&lt;/span&gt;&lt;br&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>GRADE Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Guideline and Recommendation</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
    </ENTRIES>
  </INFO>
</GLOSSARY>
